Transcatheter arterial chemoembolization with spherical embolic material for locally advanced breast cancer: first report of HepaSphere™ treatment for primary breast cancer

Abstract

A 57-year-old female was diagnosed as having primary breast cancer (invasive carcinoma of no special type), which was immunohistochemically negative for oestrogen receptor, androgen receptor and human epidermal growth factor receptor Type 2. The main tumour was 54 × 35 mm in size and was located in the internal upper area of the left breast. The tumour had markedly invaded the skin and a daughter nodule was observed in the external upper area of the ipsilateral breast. An enlarged lymph node measuring 12mm in diameter was present in the axilla and an affected parasternal lymph node was also observed. A blood test showed no abnormalities and the patient was negative for tumour markers. We performed three sessions of transcatheter arterial chemoembolization with docetaxel-loaded HepaSphere™. The treatment procedure was successfully performed in all the three sessions. No adverse events higher than Grade 3 were observed. The sizes of the primary lesion and axillary lymph node decreased to 26 × 14 mm (37% reduction) and 10mm, respectively. The parasternal lymph node completely resolved. 2 months later, left total mastectomy and axillary lymph node dissection were performed. The histopathological post-therapy effect was considered to be a mild response (Grade 1a) in the breast lesion and a complete response (Grade 3) in the axillary lymph node. The mean±standard deviation of the minor axis of the vessels embolized with spherical particles was 183.0±96.5 μm. Our results indicate that transcatheter arterial chemoembolization used together with HepaSphere can be an alternative and effective therapy for locally advanced breast cancer.

Long-term Histopathologic Follow-up of a Spherical Embolic Agent; Observation of the Transvascular Migration of HepaSphereTM

“…In DEM-TACE for primary breast cancer, which we performed previously, extravascular migration was already observed 2–5 months after the procedure. 11 Hori et al reported that extravascular leakage was already observed at 4 weeks after the procedure. 10 Bilbao et al reported that extravascular leakage was not observed at 48 h but was observed at 4 weeks after the procedure.…”

Transarterial chemoembolization as a part of multi-modality treatment with drug-eluting beads for locally advanced breast cancer: A case report

“…Kennoki at al [13] first adopted HepaSphere as a treatment choice for LABC. Intraarterial infusion of multiple anticancer drugs was carried out prior to embolization with docetaxel- or Adriamycin- loaded HepaSphere.…”

Case of squamous cell carcinoma accompanied by daughter nodules in the buttock

“…Daughter nodules include satellite metastases accompanying some tumors, including breast cancer, 5 although satellite metastases are usually present at a distance from the primary tumor and other satellite foci. DN should be strictly distinguished from satellite metastases and the term should be used only when the nodules are contiguous with the primary lesion and other DN.…”